Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- Mayo Clinic
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Imaging analysis
研究概览
简要总结
The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.
详细描述
The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants will be over the age of 21
- •Have symptoms suggestive of a neurodegenerative and/or related disorder
排除标准
- •Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes
- •Women that are pregnant or post-partum and breast-feeding will be excluded
- •Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome
- •Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts)
- •Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)
研究组 & 干预措施
Neurodegenerative symptoms
干预措施: C-11 PiB (Drug)
Neurodegenerative symptoms
干预措施: AV1451 Tau (Drug)
Neurodegenerative symptoms
干预措施: C-11 ER176 (Drug)
结局指标
主要结局
Imaging analysis
时间窗: 1 year
Longitudinal images and correlates will be measured and tracked to determine direct correlations in the brain with disease progression on a yearly basis
次要结局
未报告次要终点
研究者
Keith A. Josephs
Professor of Neurology
Mayo Clinic